REGN
RegeneronCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The near-term bull case is that the Q1 print still showed strong underlying earnings power: revenue grew 19%, Dupixent profit share accelerated, Libtayo remained strong, and EYLEA HD demand grew despite inventory and pricing friction. The packet's trusted-news set framed the quarter as an earnings beat, but detailed T+1 analyst estimate and target revisions were not available, so this is supportive rather than decisive evidence.
Posture
Mixed
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-02.
What can break
EYLEA franchise erosion remains the main risk, with management warning that additional U.S. biosimilar competition is expected in the second half of 2026. [#10-Q-2026-04-29]
Momentum
13
Value
66
Sentiment
77
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $780.00 · Bull $880.00 · Bear $620.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bearish
Target $878.58
Why
Momentum13 · Δ7d -8.7
Value66 · Δ7d +0.6
Sentiment77 · Δ7d +11.4
So what
Balanced signals (Net Bearish). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
13
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.7
Δ21d
-11.8
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+1.8
Sentiment
77
33% active weight
Current posture
7d trendImproving
Δ7d
+11.4
Δ21d
+29.2
Why this grade
Composite grade C. Momentum 12.7 / Value 65.7 / Sentiment 77.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$62.97B
Beta
0.40
Shares Out
105.1M
P/E (TTM)
18.1
P/S (TTM)
5.63
P/FCF (TTM)
22.26
Rev YoY
+0.9%
EPS YoY
+21.6%
Gross Margin
+86.3%
Op Margin
+25.9%
Net Debt
-$6.31B
Current Ratio
4.06
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology